B
BioNTech
Pioneering Individualized Medicine
Mainz, Germany (US: Cambridge, MA)
5,500+
About BioNTech
Industry:
Biotechnology
Founded:
2008
Founders:
Ugur Sahin, Ozlem Tureci
Status:
Public (NASDAQ: BNTX)
Funding & Growth
Total Raised:
$1.5B+
Valuation:
$25B+ market cap
Stage:
Public
Key Investors:
Pfizer partnership
Public markets
✓ Pros
- • mRNA technology pioneer
- • Strong COVID vaccine success
- • Heavy oncology pipeline investment
- • Cambridge, MA hub
- • Founder-led scientific culture
✗ Cons
- • German headquarters (timezone)
- • Post-COVID transition challenges
- • Fast-paced, demanding
- • High expectations